RGF® Environmental Group Releases Independent Test: PHI-PKG14 PHI-CELL® Inactivates greater than 99.9% of SARS-CoV-2 Virus in the Air and on Surfaces
RGF vs. SARS-CoV-2
RGF Photohydroionization (PHI-CELL
RGF® first developed its Photohydroionization® (PHI-CELL®) technology over 20 years ago and since then more than four million units have been installed worldwide.
RGF® has licensed its technology to many Fortune 500 companies for use in health care, food processing, military, government, marine, hospitality, residential and commercial applications. In addition, RGF®’s AOT cells have been specified in the Norovirus and MRSA protection plan of America’s largest restaurant chains, hotel chains, theme parks, cruise lines, public schools and hospitals.
Below you will find a summary of some of the testing and studies performed by third party independent labs and universities. RGF® products are not medical devices and no medical claims are made.
Testing Summary: 99+% Airborne Inactivation of MS2 Bacteriophage
The samples were plated and incubated overnight. The percent reduction associated with the HALO-LED™ treatment was 99.9% after two hours of exposure.
*Tested by Intertek Microbiology laboratory in Columbus, OH.